Highlights NexImmune, Inc.

Equities

NEXI

US65344D2080

Market Closed - Nasdaq Other stock markets 12:52:01 2024-05-31 pm EDT			5-day change	1st Jan Change
3.06 ^USD	+1.66%		-3.80%	+37.84%

Apr. 17	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 16	NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
North American Morning Briefing : Traders Await -2-	Apr. 10	DJ
NexImmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 17	CI
NexImmune Extends Partnership With Yale, JDRF for Type 1 Diabetes	23-10-24	MT
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes	23-10-24	CI
NexImmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Neximmune Announces Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-Hsct Aml At the American Society of Clinical Oncology 2023 Annual Meeting	23-06-05	CI
NexImmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
NEXIMMUNE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-28	AQ
NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
North American Morning Briefing : Muted Start Seen -2-	22-11-17	DJ
NEXIMMUNE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-14	AQ
NexImmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
NexImmune In Collaboration to Assess EBV, HTLV-1 as Therapeutic Targets in Neurological Immune Disease Pathophysiology	22-10-06	MT
NexImmune, Inc. Announces Research Collaboration with National Institute of Neurological Disorders and Stroke of the National Institutes of Health	22-10-06	CI
NextImmune Signs Service Agreement With Selexis to Develop Immunotherapies for Rare Cancers, Autoimmune Disorders	22-09-08	MT
NEXIMMUNE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-08-15	AQ
NexImmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers	22-07-14	CI
NEXIMMUNE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-05-12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NexImmune, Inc.

Equities

NEXI

US65344D2080

Highlights

Filters